<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530711</url>
  </required_header>
  <id_info>
    <org_study_id>AMELIORATE</org_study_id>
    <nct_id>NCT01530711</nct_id>
  </id_info>
  <brief_title>Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response</brief_title>
  <acronym>AMELIORATE</acronym>
  <official_title>Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pere Gines</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observe the effect of terlipressin on renal function in patients with SHR type I adjusting
      the dose based on hemodynamic response.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in arterial pressure and creatinine</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasmatic renin activity and aldosterone and noradrenaline concentration.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatorenal Syndrome reversion due to hemodynamic changes.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatorenal Syndrome Type I</condition>
  <arm_group>
    <arm_group_label>terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin and albumin</intervention_name>
    <description>Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase &lt; 10 mmHg and the creatinine values decrease &lt;25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.
Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day.</description>
    <arm_group_label>terlipressin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hepatorenal syndrome type 1.

          -  Signed informed consent.

          -  No exclusion criteria.

          -  At least 18 years old

          -  Negative pregnancy test in serum or urine in women of childbearing age, and agree to
             use adequate contraception since at least 14 days prior to the first dose of study
             drug until 14 days after the last.

        Exclusion Criteria:

          -  Hepatocellular carcinoma: exclusion of patients with hepatocellular carcinoma who
             present more than 3 nodules, single nodule larger than 5 cm, tumor portal thrombosis
             or extrahepatic tumor spread.

          -  Active bacterial infection with symptoms of systemic inflammatory response (fever,
             tachycardia, tachypnea, hypotension, septic or blood count).

          -  Cardiac or respiratory failure clinically significant.

          -  Clinically significant peripheral artery disease.

          -  A history of ischemic heart disease.

          -  Hypersensitivity to terlipressin and / or albumin or any of the excipients.

          -  Pregnancy.

          -  Septic shock.

          -  Chronic renal failure.

          -  Women in lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>German Soriano Pastor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>gsoriano@santpau.cat</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Cordoba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>jcordoba@vhebron.net</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Cirera Lorenzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICirera@parcdesalutmar.cat</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Martín Llahí, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>martinllahi@gmail.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Sánchez Delgado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>jsanchezd@tauli.cat</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moisés Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Pere Gines</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

